Content area

Abstract

The circadian clock, a fundamental biological regulator, governs essential cellular processes in health and disease. Circadian-based therapeutic strategies are increasingly gaining recognition as promising avenues. Aligning drug administration with the circadian rhythm can enhance treatment efficacy and minimize side effects. Yet, uncovering the optimal treatment timings remains challenging, limiting their widespread adoption. In this work, we introduce a high-throughput approach integrating live-imaging and data analysis techniques to deep-phenotype cancer cell models, evaluating their circadian rhythms, growth, and drug responses. We devise a streamlined process for profiling drug sensitivities across different times of the day, identifying optimal treatment windows and responsive cell types and drug combinations. Finally, we implement multiple computational tools to uncover cellular and genetic factors shaping time-of-day drug sensitivity. Our versatile approach is adaptable to various biological models, facilitating its broad application and relevance. Ultimately, this research leverages circadian rhythms to optimize anti-cancer drug treatments, promising improved outcomes and transformative treatment strategies.

The circadian rhythm has been linked to cancer cell sensitivity to therapy but tools to understand this further are limited. Here, by combining live-cell imaging and computational tools, the authors develop a high-throughput deep-phenotyping approach to evaluate circadian rhythms and use it to determine time-of-day drug sensitivity in cancer cell lines.

Details

1009240
Title
Time-of-day effects of cancer drugs revealed by high-throughput deep phenotyping
Author
Ector, Carolin 1 ; Schmal, Christoph 2 ; Didier, Jeff 3   VIAFID ORCID Logo  ; De Landtsheer, Sébastien 3   VIAFID ORCID Logo  ; Finger, Anna-Marie 4   VIAFID ORCID Logo  ; Müller-Marquardt, Francesca 5 ; Schulte, Johannes H. 6   VIAFID ORCID Logo  ; Sauter, Thomas 3   VIAFID ORCID Logo  ; Keilholz, Ulrich 7 ; Herzel, Hanspeter 8 ; Kramer, Achim 9   VIAFID ORCID Logo  ; Granada, Adrián E. 7   VIAFID ORCID Logo 

 Charité – Universitätsmedizin Berlin, Charité Comprehensive Cancer Center, Berlin, Germany (GRID:grid.6363.0) (ISNI:0000 0001 2218 4662); Humboldt-Universität zu Berlin, Faculty of Life Sciences, Berlin, Germany (GRID:grid.7468.d) (ISNI:0000 0001 2248 7639) 
 Humboldt-Universität zu Berlin, Institute for Theoretical Biology, Berlin, Germany (GRID:grid.7468.d) (ISNI:0000 0001 2248 7639) 
 University of Luxembourg, Department of Life Sciences and Medicine, Esch-sur-Alzette, Luxembourg (GRID:grid.16008.3f) (ISNI:0000 0001 2295 9843) 
 Charité – Universitätsmedizin Berlin, Institute for Medical Immunology, Berlin, Germany (GRID:grid.6363.0) (ISNI:0000 0001 2218 4662); San Francisco, Department of Anatomy, University of California, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811) 
 Charité – Universitätsmedizin Berlin, Charité Comprehensive Cancer Center, Berlin, Germany (GRID:grid.6363.0) (ISNI:0000 0001 2218 4662); University of Montpellier, Institute of Research for Development, Montpellier, France (GRID:grid.121334.6) (ISNI:0000 0001 2097 0141) 
 Charité – Universitätsmedizin Berlin, Department of Pediatric Oncology, Hematology and Stem Cell Transplantation, Berlin, Germany (GRID:grid.6363.0) (ISNI:0000 0001 2218 4662); Universitätsklinikum Tübingen, Clinic for Pediatrics and Adolescent Medicine, Tübingen, Germany (GRID:grid.411544.1) (ISNI:0000 0001 0196 8249) 
 Charité – Universitätsmedizin Berlin, Charité Comprehensive Cancer Center, Berlin, Germany (GRID:grid.6363.0) (ISNI:0000 0001 2218 4662); German Cancer Consortium (DKTK), Berlin, Germany (GRID:grid.6363.0) (ISNI:0000 0004 7865 6683) 
 Humboldt-Universität zu Berlin, Institute for Theoretical Biology, Berlin, Germany (GRID:grid.7468.d) (ISNI:0000 0001 2248 7639); Charité – Universitätsmedizin Berlin, Berlin, Germany (GRID:grid.6363.0) (ISNI:0000 0001 2218 4662) 
 Charité – Universitätsmedizin Berlin, Institute for Medical Immunology, Berlin, Germany (GRID:grid.6363.0) (ISNI:0000 0001 2218 4662) 
Publication title
Volume
15
Issue
1
Pages
7205
Publication year
2024
Publication date
2024
Publisher
Nature Publishing Group
Place of publication
London
Country of publication
United States
Publication subject
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
Document type
Journal Article
Publication history
 
 
Online publication date
2024-08-22
Milestone dates
2024-08-14 (Registration); 2023-11-07 (Received); 2024-08-13 (Accepted)
Publication history
 
 
   First posting date
22 Aug 2024
ProQuest document ID
3095292261
Document URL
https://www.proquest.com/scholarly-journals/time-day-effects-cancer-drugs-revealed-high/docview/3095292261/se-2?accountid=208611
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Last updated
2024-10-03
Database
ProQuest One Academic